GRAIL, Inc. (BMV:GRAL)

Market Cap	23.68B
Revenue (ttm)	2.67B
Net Income (ttm)	-39.13B
Shares Out	n/a
EPS (ttm)	-1,196.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	430
Average Volume	952
Open	665.02
Previous Close	n/a
Day's Range	665.02 - 665.02
52-Week Range	246.28 - 898.00
Beta	n/a
RSI	58.20
Earnings Date	Aug 12, 2025

About GRAIL

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2015
• Employees: 1,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: GRAL

Financial Performance

In 2024, GRAIL's revenue was $125.60 million, an increase of 34.90% compared to the previous year's $93.11 million. Losses were -$2.03 billion, 38.3% more than in 2023.

Financial numbers in USD